'Astellas to Acquire Ganymed Pharmaceuticals
Astellas Pharma Europe | October 28, 2016
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for Astellas to acquire Ganymed. The transaction would enable Astellasto continue to build upon its leading oncology franchise as a platform for sustainable growth.